The National Pharmaceutical Pricing Authority (NPPA) has been directed by the Department of Pharmaceuticals (DoP) to issue a public notice stating that all the prices fixed by them in 2014 without giving WPI for the calendar year, 2013 be revised by companies as per provisions of para 16(ii), if the companies so desire.
The DoP's directive in this regard came in response to a review petition filed by FDC Limited against fixation of ceiling price of Salbutamol Sulphate 2mg tablets by the NPPA. The NPPA vide price fixation Order S.O. No.1157(E) dated 28/4/2014 had fixed ceiling price of scheduled medicine Salbutamol Sulphate 2mg tablets under DPCO, 2013.
Aggrieved by the notification, FDC represented to the reviewing authority, DoP, against the price fixation. Personal hearing was granted to the petitioners by the DoP on 10.6.2014. The petitioners were represented by Ravikaran Heravatta, Manager-Commercial. On behalf of the NPPA, S.K. Bhatt, Deputy Director (Tech), Manish Goswami, Dy Director (Cost) and Naresh Arya, Dy Director(Cost) attended the hearing.
The issues involved in the review application have been examined based on the record note of discussions of the personal hearing and other documents on record. After examining the issue, the DoP ordered, “NPPA is directed to issue a public notice stating that all the prices fixed by them in 2014 without giving WPI for the calendar year, 2013 be revised by companies as per provisions of para 16(ii) , if the companies so desire.”
In yet another order while reviewing another review application of FDC Limited against fixation of ceiling price of ciprofloxacin hydrochloride ointment 0.3per cent, the DoP again directed the NPPA to allow WPI for the year 2013 for the calendar year 2013 before making the price effective from 1st April, 2014.
Earlier, the NPPA vide price fixation Order SO No 953(E) dated 27/3/2014 had fixed ceiling price of scheduled medicine ciprofloxacin hydrochloride ointment 0.3per cent under DPCO, 2013.
Aggrieved by the notification, FDC had represented to DoP against the price fixation. Personal hearing was granted to the petitioners by the DoP on 9.5.2014. The issues involved in the review application have been examined based on the record note of discussions of the personal hearing and other documents on record. After examining the issue, the DoP ordered, “NPPA is directed to allow WPI for the year 2013 for the calendar year 2013 before making the price effective from 1st April, 2014. However, the Petitioners have to maintain the ceiling price already notified by NPPA under provision to para 31 of DPCO, 2013.
The DoP's directive in this regard came in response to a review petition filed by FDC Limited against fixation of ceiling price of Salbutamol Sulphate 2mg tablets by the NPPA. The NPPA vide price fixation Order S.O. No.1157(E) dated 28/4/2014 had fixed ceiling price of scheduled medicine Salbutamol Sulphate 2mg tablets under DPCO, 2013.
Aggrieved by the notification, FDC represented to the reviewing authority, DoP, against the price fixation. Personal hearing was granted to the petitioners by the DoP on 10.6.2014. The petitioners were represented by Ravikaran Heravatta, Manager-Commercial. On behalf of the NPPA, S.K. Bhatt, Deputy Director (Tech), Manish Goswami, Dy Director (Cost) and Naresh Arya, Dy Director(Cost) attended the hearing.
The issues involved in the review application have been examined based on the record note of discussions of the personal hearing and other documents on record. After examining the issue, the DoP ordered, “NPPA is directed to issue a public notice stating that all the prices fixed by them in 2014 without giving WPI for the calendar year, 2013 be revised by companies as per provisions of para 16(ii) , if the companies so desire.”
In yet another order while reviewing another review application of FDC Limited against fixation of ceiling price of ciprofloxacin hydrochloride ointment 0.3per cent, the DoP again directed the NPPA to allow WPI for the year 2013 for the calendar year 2013 before making the price effective from 1st April, 2014.
Earlier, the NPPA vide price fixation Order SO No 953(E) dated 27/3/2014 had fixed ceiling price of scheduled medicine ciprofloxacin hydrochloride ointment 0.3per cent under DPCO, 2013.
Aggrieved by the notification, FDC had represented to DoP against the price fixation. Personal hearing was granted to the petitioners by the DoP on 9.5.2014. The issues involved in the review application have been examined based on the record note of discussions of the personal hearing and other documents on record. After examining the issue, the DoP ordered, “NPPA is directed to allow WPI for the year 2013 for the calendar year 2013 before making the price effective from 1st April, 2014. However, the Petitioners have to maintain the ceiling price already notified by NPPA under provision to para 31 of DPCO, 2013.
No comments:
Post a Comment